| First Author | Sanghrajka RM | Year | 2023 |
| Journal | iScience | Volume | 26 |
| Issue | 10 | Pages | 107831 |
| PubMed ID | 37822508 | Mgi Jnum | J:341500 |
| Mgi Id | MGI:7540190 | Doi | 10.1016/j.isci.2023.107831 |
| Citation | Sanghrajka RM, et al. (2023) KMT2D suppresses Sonic hedgehog-driven medulloblastoma progression and metastasis. iScience 26(10):107831 |
| abstractText | The major cause of treatment failure and mortality among medulloblastoma patients is metastasis intracranially or along the spinal cord. The molecular mechanisms driving tumor metastasis in Sonic hedgehog-driven medulloblastoma (SHH-MB) patients, however, remain largely unknown. In this study we define a tumor suppressive role of KMT2D (MLL2), a gene frequently mutated in the most metastatic beta-subtype. Strikingly, genetic mouse models of SHH-MB demonstrate that heterozygous loss of Kmt2d in conjunction with activation of the SHH pathway causes highly penetrant disease with decreased survival, increased hindbrain invasion and spinal cord metastasis. Loss of Kmt2d attenuates neural differentiation and shifts the transcriptional/chromatin landscape of primary and metastatic tumors toward a decrease in differentiation genes and tumor suppressors and an increase in genes/pathways implicated in advanced stage cancer and metastasis (TGFbeta, Notch, Atoh1, Sox2, and Myc). Thus, secondary heterozygous KMT2D mutations likely have prognostic value for identifying SHH-MB patients prone to develop metastasis. |
